Here is a focused DNA test that could eliminate colonoscopies for low risk adults over 50.
Two new DNA-based tests, one of them described at a meeting in Philadelphia on Thursday, hold the promise of detecting early — and sharply reducing — colon cancer, a disease that afflicts 150,000 people a year in the United States and costs an estimated $14 billion to treat.
Unlike colonoscopy, in which a seeing tube is threaded up the colon, the DNA tests are noninvasive, so more people would take them. Both tests could be brought to market within two years.
One of the tests, developed by Exact Sciences of Madison, Wis., looks in stool samples for the presence of four altered genes that are diagnostic of colon cancer. The test could catch cancerous and precancerous tumors at an early stage, when they are curable, and allow doctors to remove them promptly.
The other test looks in blood for changes in a single gene, called Septin 9, which is not in the Exact Sciences’ panel of four genes. The test has been developed by Epigenomics AG in Germany.
New DNA Tests Aimed at Reducing Colon Cancer